Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Veltman

General Practice Martinsburg, WV Medical Doctor

NPI 1740239771 CMS profile 33410

35 Aikens Center, Panhandle Medicine, Martinsburg, WV 25401

Open in the dashboard

General payments

$14,525

781 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Veltman of Martinsburg, WV is reported in the CMS Open Payments database as having received $14,525 across 781 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $627 29
2024 General $1,577 67
2023 General $1,216 69
2022 General $2,376 126
2021 General $3,562 124
2020 General $2,099 134
2019 General $3,069 232

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Veltman
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to John Veltman were reported at $627. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year John Veltman General Practice median Middle half National median
2019 $3,069 $107 $37–$285 $163
2020 $2,099 $75 $25–$213 $114
2021 $3,562 $93 $30–$272 $132
2022 $2,376 $103 $36–$279 $149
2023 $1,216 $106 $34–$276 $160
2024 $1,577 $114 $39–$290 $164
2025 $627 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,560 100 payments
  2. Lilly USA, LLC $1,756 115 payments
  3. Biohaven Pharmaceuticals, Inc. $1,645 20 payments
  4. Novo Nordisk Inc $1,121 87 payments
  5. AbbVie, Inc. $708 40 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $511 24 payments
  7. Phathom Pharmaceuticals, Inc. $462 22 payments
  8. Eisai Inc. $422 15 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $409 30 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $405 30 payments
  11. Other $4,526 298 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,156 776 payments
  2. Consulting Fee $1,200 1 payment
  3. Education $169 4 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT $2,050 50 payments
  2. FARXIGA $1,217 45 payments
  3. BREZTRI $1,028 39 payments
  4. Ozempic $858 72 payments
  5. JARDIANCE $740 53 payments
  6. RYBELSUS $691 44 payments
  7. EMGALITY $579 41 payments
  8. Kerendia $511 24 payments
  9. MOUNJARO $481 22 payments
  10. Dayvigo $422 15 payments
  11. Other $9,255 654 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for General Practice: 1,105

Drug cost

$431

Median for General Practice: $48,734

Branded share of claims

100%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 11 $431

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $325
$325 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $323
$323 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $174
$174 — —
MOUNJARO
  • Lilly USA, LLC $171
$171 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $153
$153 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

781 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record